Detection of Idiosyncratic Hepatotoxicity Before and After Marketing

First Page		Document Content
Pharmacology Hepatology Hepatotoxicity Toxicology Ximelagatran Bromfenac Food and Drug Administration Center for Drug Evaluation and Research Jaundice Medicine Health Chemistry		Detection of Idiosyncratic Hepatotoxicity Before and After Marketing Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 577,44 KB Share Document on Facebook

	FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Pharmacy Compounding Advisory Committee (PCAC) Meeting February 23-24, 2015 QUESTIONS February 23, 2015 DocID: 1b1nI - View Document
	Date of Approval: November 10, 2014 FREEDOM OF INFORMATION SUMMARY SUPPLEMENTAL NEW ANIMAL DRUG APPLICATION NADA[removed] DocID: XMr9 - View Document
	FDA Advisory Committee Docket No. FDA–2011–N–0805 DocID: Gwop - View Document
	Detection of Idiosyncratic Hepatotoxicity Before and After Marketing DocID: DA6f - View Document
	NAMFCU PRESS RELEASE ISTA PHARMACEUTICALS, INC. PAYS $15 MILLION IN SETTLEMENT OF OFF-LABEL MARKETING CLAIMS NAMFCU announced on July 17, 2013 that the states and the federal government reached an agreement with ISTA Pha DocID: zU5X - View Document